SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-001715
Filing Date
2022-01-26
Accepted
2022-01-26 16:56:07
Documents
13
Period of Report
2022-01-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20220126b_8k.htm   iXBRL 8-K 35079
  Complete submission text file 0001437749-22-001715.txt   187945

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvph-20220126.xsd EX-101.SCH 4049
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20220126_def.xml EX-101.DEF 13811
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20220126_lab.xml EX-101.LAB 18160
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20220126_pre.xml EX-101.PRE 13837
7 EXTRACTED XBRL INSTANCE DOCUMENT rvph20220126b_8k_htm.xml XML 4457
Mailing Address 19925 STEVENS CREEK BLVD. SUITE 100 CUPERTINO CA 95014
Business Address 19925 STEVENS CREEK BLVD. SUITE 100 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 22558651
SIC: 2834 Pharmaceutical Preparations